Youngevity International Company Profile (OTCMKTS:YGYI)

About Youngevity International (OTCMKTS:YGYI)

Youngevity International logoYoungevity International, Inc. is an e-commerce company. The Company operates through two segments: the direct selling segment where products are offered through a global distribution network of customers and distributors, and the commercial coffee segment where products are sold directly to businesses. The Company offers over 2,500 products to support a healthy lifestyle. All of these products, which are sold through its direct selling network, are categorized into over 11 sub-product lines. In the direct selling segment, the Company sells health and wellness, beauty product and skin care, scrap booking and story booking items, and packaged food products on a global basis, and offers a range of products through an international direct selling network. The Company is engaged in the commercial sale of coffee through its subsidiary CLR Roasters, LLC (CLR) and its subsidiary. Its brands include Cafe La Rica, Javalution Daily Grind, Javalution Royal Roast, SOZO Global and Integris.

Industry, Sector and Symbol:
  • Sector: Non-Cyclical Consumer Goods & Services
  • Industry: Non-Alcoholic Beverages
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:YGYI
  • CUSIP: N/A
  • Web:
  • Market Cap: $90.72 million
  • Outstanding Shares: 19,678,000
Average Prices:
  • 50 Day Moving Avg: $5.00
  • 200 Day Moving Avg: $5.04
  • 52 Week Range: $3.00 - $7.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 461.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $162.23 million
  • Price / Sales: 0.56
  • Book Value: $0.76 per share
  • Price / Book: 6.07
  • EBITDA: ($545,000.00)
  • Net Margins: -6.57%
  • Return on Equity: -68.76%
  • Return on Assets: -15.82%
  • Debt-to-Equity Ratio: 1.42%
  • Current Ratio: 1.04%
  • Quick Ratio: 0.30%
  • Average Volume: 13,737 shs.
  • Beta: -0.04
  • Short Ratio: 0.83

Frequently Asked Questions for Youngevity International (OTCMKTS:YGYI)

What is Youngevity International's stock symbol?

Youngevity International trades on the OTCMKTS under the ticker symbol "YGYI."

How were Youngevity International's earnings last quarter?

Youngevity International Inc (OTCMKTS:YGYI) released its earnings results on Thursday, August, 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. Youngevity International had a negative net margin of 6.57% and a negative return on equity of 68.76%. View Youngevity International's Earnings History.

When will Youngevity International make its next earnings announcement?

Youngevity International is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Youngevity International.

Who are some of Youngevity International's key competitors?

Who are Youngevity International's key executives?

Youngevity International's management team includes the folowing people:

  • Stephan Wallach, Chairman of the Board, Chief Executive Officer
  • David Briskie, President, Chief Financial Officer, Director
  • Michelle G Wallach, Chief Operating Officer, Director
  • Brad Kenson, Chief Technology Officer
  • Loren Castronovo, Chief Marketing Officer
  • Kevin Allodi, Director
  • Richard Renton, Director
  • Paul Sallwasser, Director
  • William Thompson, Independent Director

How do I buy Youngevity International stock?

Shares of Youngevity International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Youngevity International's stock price today?

One share of Youngevity International stock can currently be purchased for approximately $4.61.

MarketBeat Community Rating for Youngevity International (OTCMKTS YGYI)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about Youngevity International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Youngevity International (OTCMKTS:YGYI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Youngevity International (OTCMKTS:YGYI)
Price Target History for Youngevity International (OTCMKTS:YGYI)
Analysts' Ratings History for Youngevity International (OTCMKTS:YGYI)
No equities research coverage for this company has been tracked by


Earnings History for Youngevity International (OTCMKTS:YGYI)
Earnings by Quarter for Youngevity International (OTCMKTS:YGYI)
Earnings History by Quarter for Youngevity International (OTCMKTS YGYI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017N/AView Earnings Details
8/10/2017Q2 2017($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Youngevity International (OTCMKTS:YGYI)
Current Year EPS Consensus Estimate: $0.01 EPS
Next Year EPS Consensus Estimate: $0.01 EPS


Dividend History for Youngevity International (OTCMKTS:YGYI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Youngevity International (OTCMKTS:YGYI)
Insider Ownership Percentage: 77.00%
Insider Trades by Quarter for Youngevity International (OTCMKTS:YGYI)
Insider Trades by Quarter for Youngevity International (OTCMKTS:YGYI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/21/2015David BriskieCFOBuy10,000$0.30$3,000.00View SEC Filing  
9/2/2015Stephan WallachCEOBuy5,000$0.31$1,550.00View SEC Filing  
8/27/2015Stephan WallachCEOBuy5,000$0.32$1,600.00View SEC Filing  
8/24/2015David BriskieCFOBuy10,000$0.30$3,000.00View SEC Filing  
8/24/2015Stephan WallachCEOBuy11,800$0.30$3,540.00View SEC Filing  
6/12/2015David BriskieCFOBuy13,500$0.38$5,130.00View SEC Filing  
6/4/2015David BriskieCFOBuy24,200$0.36$8,712.00View SEC Filing  
6/4/2015William AndreoliPresidentBuy25,000$0.33$8,250.00View SEC Filing  
5/29/2015William AndreoliPresidentBuy10,000$0.39$3,900.00View SEC Filing  
3/11/2015William AndreoliPresidentBuy10,000$0.24$2,400.00View SEC Filing  
1/8/2015David BriskieCFOBuy15,000$0.24$3,600.00View SEC Filing  
12/5/2014David BriskieCFOBuy12,500$0.24$3,000.00View SEC Filing  
12/5/2014Stephan WallachCEOBuy3,000$0.24$720.00View SEC Filing  
12/3/2014Stephan WallachCEOBuy5,000$0.25$1,250.00View SEC Filing  
12/2/2014William AndreoliPresidentBuy10,000$0.25$2,500.00View SEC Filing  
12/1/2014David BriskieCFOBuy8,500$0.25$2,125.00View SEC Filing  
12/1/2014Stephan WallachCEOBuy1,000$0.26$260.00View SEC Filing  
11/26/2014Stephan WallachCEOBuy2,000$0.26$520.00View SEC Filing  
11/25/2014Stephan WallachCEOBuy4,900$0.24$1,176.00View SEC Filing  
11/21/2014David BriskieCFOBuy7,500$0.25$1,875.00View SEC Filing  
11/21/2014Stephan WallachCEOBuy15,550$0.25$3,887.50View SEC Filing  
11/19/2014Stephan WallachCEOBuy3,000$0.23$690.00View SEC Filing  
11/18/2014David BriskieCFOBuy10,000$0.24$2,400.00View SEC Filing  
9/5/2014David BriskieCFOBuy8,400$0.25$2,100.00View SEC Filing  
9/3/2014David BriskieCFOBuy19,000$0.24$4,560.00View SEC Filing  
8/28/2014David BriskieCFOBuy30,000$0.23$6,900.00View SEC Filing  
8/27/2014David BriskieCFOBuy24,500$0.23$5,635.00View SEC Filing  
8/25/2014David BriskieCFOBuy15,000$0.23$3,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Youngevity International (OTCMKTS:YGYI)
Latest Headlines for Youngevity International (OTCMKTS:YGYI)
Loading headlines, please wait.



Youngevity International (YGYI) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.